Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
P
PLRZ
vs
S&P 500
S&P 500
Over the past 12 months, PLRZ has significantly outperformed S&P 500, delivering a return of +36% compared to S&P 500's +12% growth.
Stocks Performance
PLRZ vs S&P 500
Performance Gap
PLRZ vs S&P 500
Performance By Year
PLRZ vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Polyrizon Ltd
Glance View
Polyrizon Ltd. is a biotechnology company focused on the nose as a first line of defense against airborne threats. It develops polymer-based nasal products that are designed to form a protective barrier in the nasal cavity, helping trap allergens, viruses, or other irritants before they can reach deeper into the body. The company’s work is centered on simple, locally applied sprays or gels rather than pills or systemic drugs. The company sells its technology through product development and, if successful, through licensing or commercialization deals with larger pharmaceutical or healthcare partners. Its main customers would be consumers, healthcare providers, or corporate partners depending on the final product form and approval path. In practice, Polyrizon aims to turn its nasal protection platform into products that can be used for prevention or symptom reduction in everyday respiratory and allergy settings. What makes Polyrizon different is its role at the front end of the healthcare value chain. Instead of treating disease after it spreads through the body, it tries to block exposure at the point of entry. That puts the company in a specialized part of biotech where the main challenge is proving that a simple physical barrier can work reliably, safely, and better than ordinary sprays or over-the-counter options.